The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients
Koichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta, Takashi Okabe, Seiya Hattori, Ryo Yamashita, Shunsuke Yoshimine, Suguru Shirotake, Ryuto Nakazawa, Kazuhiro Matsumoto, Ryuichi Mizuno, Satoshi Hara, Masafumi Oyama, Takeshi Masuda, Masashi Niwakawa, Mototsugu Oya
Topics & Concepts
PembrolizumabMedicineInternal medicineNeutrophil to lymphocyte ratioOncologyGastroenterologyCancerBiomarkerCarcinomaPopulationLymphocyteImmunotherapyChemistryEnvironmental healthBiochemistryBladder and Urothelial Cancer TreatmentsInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and Biomarkers